Alzecure: Comment on new preclinical TrkA-NAM data - Redeye
Redeye endorses the new preclinical data presented by Alzecure at IASP, indicating an analgesic and anti-inflammatory effect with its preclinical TrkA-NAM program. The program is still in the early stage, and we think that it will take some time for a selected candidate to reach the clinic. However, we think the generated data so far is strong and note that interest in the program still could be high at the preclinical stage.
Länk till analysen i sin helhet: https://www.redeye.se/research/856301/alzecure-comment-on-new-preclinical-trka-nam-data?utm_source=finwire&utm_medium=RSS